Understand the physiological determinants of extent and rate of absorption

Similar documents
Biopharmaceutics Lecture-11 & 12. Pharmacokinetics of oral absorption

Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment

Basic Concepts of TDM

Pharmacokinetics Overview

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations

Determination of bioavailability

Clinical Pharmacology. Pharmacodynamics the next step. Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand

Define the terms biopharmaceutics and bioavailability.

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA5128 Dose Optimization II Case Study I Spring 2013

BASIC PHARMACOKINETICS

PHA Final Exam Fall 2006

Rational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell

Pharmacodynamic principles and the time course of immediate drug effects

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

BIOPHARMACEUTICS and CLINICAL PHARMACY

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Section 5.2: Pharmacokinetic properties

Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017

PHARMACOKINETICS OF DRUG ABSORPTION

Lippincott Questions Pharmacology

Pharmacokinetic parameters: Halflife

Pharmaceutics I صيدالنيات 1. Unit 2 Route of Drug Administration

1. Immediate 2. Delayed 3. Cumulative

PHA Spring First Exam. 8 Aminoglycosides (5 points)

Volume of Distribution. Objectives. Volume of Distribution

Pharmacokinetics of Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Delayed Drug Effects. Distribution to Effect Site. Physiological Intermediate

Multiple IV Bolus Dose Administration

PHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

UNIVERSITY OF THE WEST INDIES, ST AUGUSTINE

General Principles of Pharmacology and Toxicology

General Principles of Pharmacology and Toxicology

Lecture 1: Physicochemical Properties of Drugs and Drug Disposition

Pharmacokinetics I. Dr. M.Mothilal Assistant professor

Pharmacodynamics & Pharmacokinetics 1

WHY... 8/21/2013 LEARNING OUTCOMES PHARMACOKINETICS I. A Absorption. D Distribution DEFINITION ADME AND THERAPEUIC ACTION

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHARMACOKINETICS SMALL GROUP I:

Pharmacodynamics. Delayed Drug Effects. Delayed and Cumulative Effects

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Winston Spencer Liauw Cancer Care Centre, St George Hospital, Gray Street, Kogarah NSW 2217, Australia

Pharmacokinetics PCTH 325. Dr. Shabbits September 12, C t = C 0 e -kt. Learning Objectives

Pharmacokinetic Calculations

Pharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen

1. Gastric Emptying Time Anatomically, a swallowed drug rapidly reaches the stomach. Eventually, the stomach empties its content in the small

TDM. Measurement techniques used to determine cyclosporine level include:

PHA5128 Dose Optimization II Case Study 3 Spring 2013

Chapter 3 Drug Absorption and Bioavailability

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

One-Compartment Open Model: Intravenous Bolus Administration:

Pharmacogenetics and Pharmacokinetics

TDM. Generally, hepatic clearance is determined by three main factors: These three factors can be employed in the following equation:

DMPK. APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology

The science behind generic drugs

Biomath M263 Clinical Pharmacology

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

2- Minimum toxic concentration (MTC): The drug concentration needed to just produce a toxic effect.

Pharmacokinetics and bioavailability derived from various body fluids. Saliva samples instead of plasma samples

Assem Al Refaei. Sameer Emeish. Dr.Alia. Hodaifa Ababneh & Abdullah Shurafa

Osnove farmakokinetike. Aleš Mrhar. Prirejeno po. A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne,

Pharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist

Development of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization

Guideline for Bioequivalence Studies of Generic Products

Interchangeable Drug Products - Additional Criteria

C OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to:

Clinical Trials A Practical Guide to Design, Analysis, and Reporting

METHODS OF STUDYING BIOAVAILABILITY AND BIOEQUIVALENCE

Problem Set for Fundamentals 9 Oct 2013

Noncompartmental Analysis (NCA) in PK, PK-based Design

NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A

abnormally high compared to those encountered when animals are fed by University of Iowa, Iowa City, Iowa, U.S.A.

Thus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.

Volume 1(3) May-June 2013 Page 351

Mechanisms of Drug Action

Metformin: Mechanistic Absorption Modeling and IVIVC Development

Applied Biopharmaceutics & Pharmacokinetics Sixth Edition

PHA First Exam Fall 2013

DRUG ELIMINATION II BILIARY EXCRETION MAMMARY, SALIVARY AND PULMONARY EXCRETION

PHA Final Exam Fall 2001

Clinical Endpoint Bioequivalence Study Review in ANDA Submissions. Ying Fan, Ph.D.

A REVIEW ON DOSAGE REGIMEN

Human Body Drug Distribution

Children are small adults and babies are young children

Case Study 2 Answers Spring 2006

Received: ; Revised; Accepted: A REVIEW ON BIOAVAILABILITY AND BIOEQUIVALENCE STUDY Shashi Kant*, Bharat Parashar

Bioequivalence of Inhaled Corticosteroids. -with emphasis on Pharmacokinetic Tools.

PHAR 7633 Chapter 20 Non Compartmental Analysis

PHA 5128 Spring 2000 Final Exam

Helmut Schütz. The Global Bioequivalence Harmonisation Initiative. 12 April 2018 [Session II: Necessity of multiple dose studies in BE testing] 1

PROFILE SIMILARITY IN BIOEQUIVALENCE TRIALS

DRAFT GUIDANCE DOCUMENT Comparative Bioavailability Standards: Formulations Used for Systemic Effects

Effect of Septilin A Herbal Preparation on Pharmacokinetics of Carbamazepine in Rabbits

Effects of Liver Disease on Pharmacokinetics

DESIGN AND DEVELOPMENT OF COLON TARGETED DRUG DELIVERY SYSTEM OF 5 FLUORURACIL & METRONIDAZOLE

Name: UFID: PHA Exam 2. Spring 2013

POPULATION PHARMACOKINETICS RAYMOND MILLER, D.Sc. Daiichi Sankyo Pharma Development

Transcription:

Absorption and Half-Life Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand Objectives Understand the physiological determinants of extent and rate of absorption Be able to describe bolus, first-order and zero-order input processes Learn the definition of half-life Be able to describe the time course of drug accumulation during constant rate input and elimination after input stops Appreciate the applications of absorption and half-life concepts to clinical practice 3 Absorption Extent of Absorption Drug absorption can be described by two quite distinct factors: The extent of absorption reflects the total amount of drug entering the body. It is not time dependent. The rate of absorption determines how quickly the drug enters the body. The rate typically changes with time. Rate of Absorption

4 Extent (F) Fraction Absorbed (f)» into portal vein from gut» physicochemistry theophylline (00%) (small,unionized) gentamicin (< 5%) (large, ionized)» metabolism/transport simvastatin (50%?) (CYP3A4) digoxin (65%) (PGP transporter) The extent of oral absorption can be considered in parts. The first part is the fraction of drug absorbed across the gut wall (f). This describes how much drug gets from the gut into the portal venous system. It is determined in part by physicochemical properties. Small, unionized molecules e.g. theophylline, are almost completely absorbed across the gut wall. Large, ionized molecules like gentamicin cross membranes with difficulty and only a small fraction is absorbed across the gut wall. Many drugs can cross the luminal cell membrane but are then metabolized in the gut wall (typically by CYP3A4 e.g. simvastatin) and/or transported out of the cell back into the gut lumen (typically by P-glycoprotein e.g. digoxin). 5 Extent (F) First Pass Extraction (ER)» drug removed while passing through liver» organ clearance and blood flow morphine (60%) ethanol (0-70%) Hepatic blood flow is one of the determinants of hepatic clearance. If the intrinsic clearance of the liver (i.e. the metabolizing enzyme capacity) is high then almost all the drug entering the liver may be metabolized as it passes through the liver. This means most of the drug entering the liver is extracted. This is called first pass extraction. Hepatic extraction ratio (ER) is the fraction of drug entering the liver that is extracted. Morphine has a high intrinsic hepatic clearance and about 60% of morphine is removed by first pass extraction after an oral dose. The hepatic extraction is determined both by the blood flow and by the intrinsic clearance. If blood flow is low then this gives the liver plenty of time to extract drug and extraction ratio will be high. On the other hand if the blood flow is high then drug can rush through the liver without being given a chance to be metabolized. If clearance is low then less drug is metabolized per unit time and extraction will be low. If clearance is high then more drug is metabolized per unit time and extraction will be high. The extraction of ethanol by the liver is sensitive to the rate of delivery to the liver which is largely determined by the rate of absorption. If ethanol absorption is slowed down e.g. by food, then hepatic extraction is more effective and less ethanol reaches the systemic circulation.

6 Extent (F) F = f ( - ER ) The overall extent of absorption is called the bioavailability. It can be calculated from the product of the fraction absorbed across the gut (f) and the hepatic extraction ratio (ER). For morphine if we assume f of and ER of 0.6 then oral bioavailability will be 40%. It is the fraction of the administered dose that reaches the systemic circulation. e.g. morphine F= ( - 0.6) = 0.4 7 Input Processes Bolus e.g. Intra-venous injection Zero-Order e.g. Constant rate I infusion First-Order e.g. Intra-muscular injection The rate of drug absorption can be described by one of 3 types of process. Bolus input means absorption is instantaneous. It is approximated by rapid intra-venous injection. Zero-order input means the absorption rate is constant for some defined period of time. This can be achieved by a constant rate intra-venous infusion. It can also be approximated by some kinds of oral dosing. First-order input means the absorption rate is proportional to the amount (or concentration) of drug at the absorption site. Typically this means that the absorption rate is higher immediately after the dose is given and the rate then decreases as drug is absorbed. Intra-muscular injection of drugs provides an example of a firstorder input process. Oral absorption of drugs is often similar to a first-order process. 8 Rate Zero-Order» Stomach emptying (Tmax) physiological control» Slow Release Formulation (Tk0) pharmaceutical control C( Rate e t The stomach is not an organ of absorption. ery little drug is absorbed across the stomach wall. Drugs (and almost anything else) are absorbed primarily in the small intestine. When drugs dissolve rapidly in the stomach the rate of emptying of the stomach determines the delivery rate of drug to the duodenum. Absorption from the duodenum is usually rapid and the rate limiting factor is the rate of gastric emptying. As a rough approximation the rate of gastric emptying occurs at a constant rate. It is like a constant rate infusion from the stomach to the duodenum. Many drugs are absorbed at the same rate because it is gastric emptying not the drug that determines how quickly the drug gets into the blood. Some drug formulations are specifically designed not to dissolve quickly. This means the drug formulation, not physiology, can be the rate limiting factor for absorption. Slow release (also known as controlled release or modified release)

formulations can often appear to make input similar to a zero-order input process. For zero-order processes the key parameter is the duration of the process (Tk0). The equation above predicts the time course of drug concentration in the blood from a constant rate input before the input process ends. 9 Zero-Order Input This graph shows the time course of drug concentration and associate rates of elimination and input for a constant rate input over hour. Note that the peak concentration occurs at the end of the constant rate input. See http://clinpharmacol.fmhs.auckland.ac. nz/docs/absorption-andelimination.xlsx for more details of how this is calculated. 0 Rate First Order» Intestinal Absorption (KA) Diffusion limited Absorption Thalf = 0.7/KA Complete after 4 x absorption Thalf Dose Ka C( e Ka t e Ka t Absorption rate across the gut wall can be described by a first order process. The proportionality constant relating drug amount at the site of absorption to the rate of absorption is often called KA. This is a first order rate constant and is exactly related to the corresponding half-life for the absorption process. The absorption half life can be calculated from KA using the natural log of (which is approximately 0.7) i.e. absorption halflife=0.7/ka. The equation above predicts the time course of drug concentration in the blood from a first-order input process. The time of the peak concentration occurs when the rate of absorption is equal to the rate of elimination. Absorption is more than 90% complete after 4 absorption half-lives. The absorption half-life should not be confused with the elimination half-life. Typical absorption half-lives are less than 0.5 hour while elimination halflives are often several hours or days.

First-Order Input This graph shows the time course of drug concentration and associates rates of elimination and input for a firstorder input. Note that the peak concentration occurs when the absorption rate is equal to the elimination rate at around.5 hours. See http://clinpharmacol.fmhs.auckland.ac. nz/docs/absorption-andelimination.xlsx for more details of how this is calculated. Applications I/Oral Dose conversion Time to Peak Concentration/Effect» Important for use of insulin (see Lipska 07) Substitution of Generic Medicines» Rate (Cmax, Tmax)» Extent (Area under the Curve, AUC) The extent of absorption (bioavailability, F) is used to convert intravenous doses to an equivalent oral dose. An intravenous dose should be divided by F to get the equivalent oral dose e.g. digoxin has an oral bioavailability of about 67%. An intravenous dose of 500 micrograms would correspond to an oral dose of 750 micrograms. The rate of drug absorption is a key determinant of the time of peak concentration and thus of the peak effect. Note that for drugs with an immediate effect the peak effect is the effect at the time (Tmax) of the peak concentration (Cmax). The peak effect is not the same as the maximum possible effect of a drug (Emax). Lipska KJ, Hirsch IB, Riddle MC. Human insulin for type diabetes: An effective, less-expensive option. JAMA. 07;38():3-4. Generic medicines are an important part of controlling drug costs for healthcare. Generic drugs are typically much cheaper than the originator product. Regulatory authorities (e.g. MedSafe in NZ, FDA in USA) use the rate and extent of absorption to judge if a generic drug is bioequivalent to the originator product. Rate is usually judged on the basis of equivalent Cmax and Tmax while extent is judged on equivalent area under the concentration time curve (AUC).

3 Half-Life Absorption Elimination Half-lives describe first-order processes. First-order processes are also often called exponential because an exponential function can be used to predict the time course of a first-order process. Half-lives are commonly used in pharmacokinetics to describe drug absorption and elimination. The elimination half-life also determines how quickly a drug accumulates. 4 T Half-Life ln() The elimination half-life is determined by clearance () and the volume of distribution (). A proportionality constant, ln(), is needed to calculate the half-life. A useful approximation to ln() is 0.7. T 0.7 5 Half-Life The origin of using ln() as the proportionality constant can be shown by deriving the half-life from a differential equation for drug elimination. dc C dt t C( C e 0 ln(0.5) T T ln() T 0.5 e ln() T

%Css 6 Time % Css Concentration 0 0 00 50 50 75 5 3 87.5.5 4 93.8 6.5 5 96.9 3. 6 98.4.6 7 99. 0.8 8 99.6 0.4 Elimination and Accumulation Conc 00 90 80 70 60 50 40 30 0 0 0 0 4 6 8 Time (half-lives) 00 90 80 70 60 50 40 30 0 0 0 This table and graph show how elimination and accumulation are mirror images of each other. After one half-life a drug will be 50% eliminated. If a drug is administered by constant rate infusion (zero-order) it will accumulate to 50% of the steady state value after one half-life. If input continues then after half-lives the concentration reaches 75% of steady state. Two half-lives after input stops then 75% of the drug will be eliminated. It is useful to learn the fraction of drug eliminated after,, 3 and 4 half-lives. After 4 half-lives elimination and accumulation can be considered essentially complete. 7 Conc 0 8 6 4 0 8 Accumulation Constant q8h q6h This graph illustrates the time course of a drug (theophylline) given by constant rate infusion or by intravenous bolus dose every 8 h or every 6 h. the dose has been chosen so that the same total amount is given every 6 h. The average steady state concentration is the same for all 3 dosing regimens. Although the bolus dose regimens have swings between peak and trough they accumulate at exactly the same rate as the constant rate infusion. 6 4 0 0 0 40 60 80 00 Time 8 Accumulation Factor The accumulation factor (AF) is the ratio of the concentration at steady state to the concentration after the first dose at the same time after the dose. Conc( AF Conc( at Steady State after First Dose AF e / Dosint All drugs accumulate. The extent of accumulation depends on the dosing interval and the half-life. A formula for predicting accumulation is shown above. The accumulation factor (AF) is the ratio of the concentration at steady state to the concentration after the first dose at the same time after the dose. If the dosing interval is equal to the halflife then the accumulation factor is exactly. Dosint = Dosing Interval

9 Applications Accumulation/Elimination» Time to Steady State» Time to Eliminate Drug ~ 4 x Elimination Half-Life Absorption» Time to Reach Peak Concentration Tmax is ~ 3 x Absorption Half-life For accumulation of a drug it is useful to predict that 50% accumulation is reached after one half-life and 75% after half-lives. After 4 half-lives the drug accumulation will be close to steady state. Drug elimination is similar in time course to drug accumulation. Essentially all drug is eliminated after 4 half-lives. The absorption half-life can be used to predict the time (Tmax) of peak concentration for many drugs. Because the peak occurs when drug absorption is equal to drug elimination it happens before drug absorption is complete. An approximate way to predict Tmax is at 3 times the absorption half-life.